Vitavita schreef op 12 november 2016 16:47:
Update Q3-2016: "Cell Factory
The broad international patent on MSC-derived extracellular vesicles (including exosomes) has been granted in Europe. The patent covers use of extracellular vesicles (EVs) in treatment of acute and chronic inflammatory and autoimmune diseases. Esperite’s R&D business unit The Cell Factory is leading an international consortium focused on clinical translation of the EVs-based drugs in treatment of drug-resistant epilepsy and Crohn’s disease.
Esperite’s goal, with Cell Factory, is to become a leader in development and production of extracellular vesicles drugs in treatment of different indications i.e. graft versus host disease (GvHD) after solid organ and cell transplantations, arthritis, multiple sclerosis, cystic fibrosis, stroke, traumatic brain and spinal cord injury, newborn encephalopathy, and type 1 diabetes among others.
EVs including exosomes are nanometre-size, natural biological particles secreted by different types of cells in vivo and in vitro. They contain proteins, growth factors, mRNA and other molecules responsible for the therapeutic effect of MSCs. In addition, EVs have several advantages over allogenic MSCs e.g.: up to 10-times lower production costs, no risk of uncontrolled proliferation and differentiation, lower risk of immune response and easy and safe delivery into different tissues and organs in vivo. High stability allows for easy transport and storage of the “ready-to-use” products."
Dit biedt perspectief, ik zie uit naar de volgende stap.
Daarnaast zal de bekendmaking van de samenwerkingspartner interessant zijn.